CRIP3 and pachyonychia congenita: One recent report identified a 3-marker urine-based panel assay consisting of miR-24, miR-30c and CRIP3 methylation which exhibited a high NPV of 91% for reclassifying low-grade into high-grade cancers in a retrospective cohort of 103 PC patients on AS [55].